Comparative efficacy of Chinese herbal injections for treating acute cerebral infarction: a network meta-analysis of randomized controlled trials

Liu, Shi; Wu, Jia-Rui; Zhang, Dan; Wang, Kai-Huan; Zhang, Bing; Zhang, Xiao-Meng; Tan, Di; Duan, Xiao-Jiao; Cui, Ying-Ying; Liu, Xin-Kui

doi:10.1186/s12906-018-2178-9

BMC Complementary Medicine and Therapies

Table 2 Characteristics of the studies included in this meta-analysis

From: Comparative efficacy of Chinese herbal injections for treating acute cerebral infarction: a network meta-analysis of randomized controlled trials

Study	Acute phase	Sex (M/F)	Age	Experimental group			Control group			Course	Outcomes	ADRs/ADEs
Study	Acute phase	Sex (M/F)	Age	N	T1	Dosage	N	T2	Dosage	Course	Outcomes	ADRs/ADEs
Yu YC 2014	72 h	38/30	62.5 (44–76)	34	XST1	500 mg	34	AADN	–	14d	(1)	None
Yu YM 2009	72 h	71/45	62.5 (40–72)	58	DH	20 ml	58	FFDS	20 ml	15d	(1)(2)	Unclear
Yu Y 2015	72 h	35/21	54.3 (38–71)	28	XST1	500 mg	28	FFDS	20 ml	14d	(1)(2)	6
Zhang ZJ 2008	74 h	41/30	64.3	35	SX	100 ml	36	FFDS	20 ml	14d	(1)	None
Zheng XD 2007	72 h	39/21	66.4	30	YXDM	20 mL	30	FFDS	30 ml	14d	(1)	None
Zhou SJ 2011	1 M	46/34	62 (42–75)	40	SX	100 ml	40	AADN	–	14d	(1)(2)	None
Zhou SF 2009	48 h	52/42	65.6 (62–86)	48	SX	200 ml	46	FFDS	20 mL	21d	(1)(2)	10
Zhou SH 2013	72 h	50/40	62	45	SXN	20 ml	45	AADN	–	14d	(1)(4)	None
Xu XY 2011	12 h	40/20	55.9 (45–73)	30	YXDM	20 ml	30	DS	20 ml	21d	(1)(2)(3)	Unclear
Xie S 2011	24 h	42/30	61.4 (53–78)	36	SXT	6 ml	36	FFDS	20 ml	14d	(1)	None
Xie YG 2010	48 h	39/31	61.6 (50–76)	35	SXT	6 ml	35	DZHS	50 mg	14d	(1)(2)	None
Xu LL 2011	72 h	48/34	63.0 (55–81)	42	LI	120 mg	42	AADN	–	14d	(1)(2)	Unclear
Xu XQ 2012	72 h	64/44	57.9	54	YXDM	20 ml	54	FFDS	20 ml	14d	(1)(2)	1
Yang HJ 2007	24 h	50/34	53.6 (39–75)	48	DSCXQ	10 ml	36	FFDS	10 ml	30d	(1)(2)	1
Yang YF 2012	48 h	–	68	112	DH	30 ml	101	AADN	–	21d	(1)(2)	Unclear
Yao QY 2010	72 h	64/40	70.8 (54–82)	56	SXT	6 ml	48	LI	12 ml	14d	(1)(2)	2
Yao J 2010	72 h	37/27	60.5 (49–76)	32	YXDM	20 ml	32	DZHS	50 mg	14d	(1)(2)	None
Xie RP 2010	72 h	52/28	42–80	40	SXN	20 ml	40	FFDS	20 mL	15d	(1)	None
Tan SY 2016	72 h	49/37	39–82	43	DH	30 ml	43	AADN	–	14d	(1)(2)	None
Wang WP 2015	72 h	49/41	68.2 (60–78)	45	SXN	20 mL	45	FFDS	20 mL	14d	(1)(2)	Unclear
Ren HM 2009	72 h	38/26	40–78	32	SX	100 ml	32	AADN	–	14d	(1)(2)	None
Sun HJ 2013	72 h	42/36	60.9 (40–70)	39	LI	120 mg	39	AADN	–	14d	(1)(2)	Unclear
Tang JP 2013	72 h	47/45	51.8 (43–73)	46	HHHSS	100 mg	46	AADN	–	14d	(1)(2)	None
Tang FY 2009	72 h	39/33	64.0 (50–78)	36	DZHS	50 mg	36	AADN	–	14d	(1)(2)	None
Tang XJ 2013	72 h	45/33	58	39	YXDM	20 mg	39	AADN	–	14d	(1)(2)	None
Wang L 2010	48 h	26/22	65.6 (62–86)	40	SX	200 mL	40	FFDS	20 mL	21d	(1)(2)	Unclear
Wang YL 2013	168 h	33/23	32–88	28	SXT	6 ml	28	DZHS	40 ml	14d	(2)	Unclear
Lan Y 2015	72 h	41/39	54–72	40	DSCXQ	10 ml	40	AADN	–	14d	(1)(2)	3
Li M 2014	24 h	63/17	48–76	40	DH	30 ml	40	AADN	–	14d	(2)	Unclear
Liu YP 2010	72 h	45/35	51–71	40	DH	40 ml	40	AADN	–	15d	(1)	1
Ma J 2010	24 h	29/31	59.1 (50–68)	30	DZHS	20 mg	30	AADN	–	14d	(1)(2)	Unclear
Ma J 2015	72 h	49/41	65.5 (45–79)	45	DH	20 ml	45	AADN	–	28d	(1)(4)	Unclear
Chen H 2015	24 h	74/60	59.4 (46–87)	67	SXT	6 ml	67	AADN	–	14d	(1)(2)	5
Luan T 2014	48 h	52/43	57.5	50	XST2	0.4 g	45	DS	20 ml	15d	(1)(4)	7
Huang ML 2012	72 h	158/142	62.6 (42–71)	150	XST1	500 mg	150	DS	25 ml	14d	(1)	1
Li X 2015	72 h	129/71	62.9	100	HHHSS	0.1 g	100	AADN	–	14d	(1)(2)	Unclear
Ma ZL 2011	72 h	74/46	62.8 (45–84)	60	HHHSS	0.1 g	60	AADN	–	14d	(1)(2)	None
Zhang Y 2012	48 h	52/28	57.5 (35–80)	40	DSCXQ	100 mg	40	AADN	–	14d	(1)(2)	1
Liu M 2014	48 h	79/57	60.2 (40–76)	68	DSCXQ	10 mL	68	AADN	–	14d	(1)(2)	2
Chen YC 2011	72 h	44/24	57.9	34	YXDM	20 ml	34	FFDS	20 ml	14d	(1)(2)	1
Yang RF 2013	48 h	52/48	60.8 (30–83)	50	SXT	6 g	50	AADN	–	14d	(1)	Unclear
Lin YF 2008	72 h	39/21	66.5	30	YXDM	20 ml	30	FFDS	20 ml	14d	(1)(3)	None
Peng T 2006	48 h	51/48	68	49	SXT	7 ml	50	FFDS	20 ml	14d	(1)(3)	1
Li XH 2011	168 h	–	63.5(40–78)	120	SXN	20 ml	120	AADN	–	14d	(1)(2)	Unclear
Liu L 2015	6-72 h	74/46	61.4 (39–76)	60	DH	20 ml	60	SXN	20 ml	14d	(1)	None
Zhang YH 2010	6-72 h	62/34	58.9 (39–81)	48	DH	30 ml	48	XST2	400 mg	14d	(1)(2)	5
Fan J 2006	72 h	56/32	64 (41–82)	44	YXDM	20 ml	44	FFDS	20 ml	14d	(2)	Unclear
Liu HY 2014	96 h	67/57	61.9 (38–83)	64	XST2	0.4 g	60	FFDS	30 ml	15d	(1)	None
Li FQ 2010	72 h	74/46	64	60	YXDM	30 ml	60	FFDS	40 ml	15d	(1)	Unclear
Lian CL 2013	360 h	49/43	62 (43–77)	46	LI	120 mg	46	AADN	–	30d	(1)	None
Chen S 2006	72 h	81/53	67.9	70	XST2	800 mg	64	XST1	10 ml	14d	(1)(2)	None
Cao LZ 2012	72 h	71/9	59.3	40	XST2	500 mg	40	FFDS	1.0 g	14d	(1)(2)	Unclear
Liu Y 2009	72 h	79/43	65.1 (43–73)	62	SXT	6 ml	60	XST2	8 ml	14d	(1)	1
Luo XD 2011	72 h	35/25	61.8	30	XST2	0.4 g	30	AADN	–	14d	(1)(2)	3
Liao MJ 2014	6-72 h	43/17	62.5 (36–80)	30	HHHSS	100 ml	30	XST2	400 mg	14d	(1)	Unclear
Shi JL 2010	72 h	51/33	62	42	YXDM	20 ml	42	LI	200 mg	30d	(2)	Unclear
Ni H 2010	24 h	61/55	62.7 (54–74)	59	SXN	20 ml	57	AADN	–	14d	(1)	Unclear
Li CP 2007	8-72 h	106/54	63.8 (42–85)	80	SXN	10-20 ml	80	AADN	–	14d	(1)	Unclear
Zhou ZP 2011	24 h	48/33	62.2	42	DZXX	30 ml	39	AADN	–	15d	(1)	Unclear
Chen C 2015	72 h	37/31	67.5	34	SXT	6 ml	34	XST2	400 mg	14d	(1)(2)	14
Chen JY 2012	72 h	73/35	67 (40–76)	54	SXT	6 ml	54	FFDS	20 ml	14d	(1)(2)	Unclear
Luo QY 2007	72 h	54/36	63.6 (37–81)	45	SXN	6 ml	45	AADN	20 ml	14d	(1)	None
Chen J 2007	72 h	45/35	61	40	YXDM	20 ml	40	MLN	20 ml	15d	(1)(2)(3)	Unclear
Zhang XL 2005	6d	37/13	35–80	26	MLN	20 ml	24	FFDS	20 m l	21d	(2)	None

M male, F female, AVG average, E experimental group, C control group, W week, D day, AADN aspirin + anticoagulants + dehydrant + neuroprotectant, DH Danhong injection + AADN, DS Danshen injection + AADN, DSCXQ Danshenchuangxiongqin injection + AADN, DZHS Dengzhanhuasu injection + AADN, DZXX Dengzhanxixin injection + AADN, FFDS Fufangdanshen injection + AADN, HHHSS Honghuahuangsesu injection + AADN, SX Shenxiong glucose injection + AADN, SXT Shuxuetong injection + AADN, XST1 Xueshuantong injection + AADN, XST2 Xuesetong injection + AADN, LI Ligustrazine injection + AADN, YXDM Yinxingdamo injection + AADN, SXN Shuxuening injection + AADN, MLN Mailuoning injection + AADN, ADRs adverse drug reactions, ADEs adverse drug events; (1): markedly effective rate; (2): neurological impairment; (3): death; (4): activities of daily living function; N: sample size; T1: therapy of experiment; T2: Therapy of control; N:Number of studies; −: No report

Back to article page

ISSN: 2662-7671

Contact us

Submission enquiries: bmccomplementarymedicineandtherapies@biomedcentral.com
General enquiries: ORSupport@springernature.com